Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

ACADIA Pharmaceuticals Raises FY2025 Sales Guidance from $1.045B-$1.095B to $1.070B-$1.095B vs $1.072B Est

Author: Benzinga Newsdesk | November 05, 2025 04:44pm

Full Year 2025 Financial Guidance

Total Revenues in the range of $1.070 to $1.095 billion, compared with the prior guidance range of $1.045 to $1.095 billion*.
NUPLAZID net product sales in the range of $685 to $695 million, compared with the prior guidance range of $665 to $690 million.
DAYBUE net product sales in the range of $385 to $400 million, compared with the prior guidance range of $380 to $405 million*.
R&D expense in the range of $335 to $345 million, compared with the prior guidance range of $330 to $350 million.
SG&A expense in the range of $540 to $555 million, compared with the prior guidance range of $535 to $565 million.

Posted In: ACAD